Figure 7

Anti IL-6R antibody treatment did not ameliorate lung adenocarcinoma.

(a)- Experimental design is shown. (b)- Flow cytometry analysis of Foxp-3+CD25+ cells gated on CD4+ lung T-cells from naïve or tumour bearing wild-type mice injected with LL/2-luc-M38 cells and treated with anti-IL6R antibody or IgG1 isotype control as compared to untreated mice. Data are shown as mean percentage ± s.e.m. using student's t-test *P,0.05; **P,0.01 (N = 10–11 per group). (c),(d)-Gene array analysis of RNA, isolated from CD4⁺ lung T-cells of tumour bearing wild-type mice treated with anti-IL6R antibody or untreated. The fold-change of the mRNA expression of significantly altered genes is shown as a heatmap (c) and as a bar chart (d) (N = 3 per group). (e),(f),(g)- Quantitative Real-time PCR analysis of Il17 (e), Rorc (f) and Batf (g) mRNA expression in CD4+ T-cells, cultured with anti-CD3 and anti-CD28 antibody. CD4⁺ T-cells were isolated from the lungs of naïve or tumour bearing wild-type mice injected with LL/2-luc-M38 cells and treated with anti-IL6R antibody or IgG1 isotype control compared to untreated mice. Data are shown as mean values ± s.e.m. Sudent's t-test was used. * P,0.05 (N = 10–11 per group).